A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects With Ulcerative Colitis Who Completed the Study M11-290
Latest Information Update: 09 May 2025
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 01 May 2025 Safety end point "Number of Participants with Adverse Events (AEs)" has been added to primary endpoints.
- 01 May 2025 Status changed from active, no longer recruiting to completed.
- 18 Feb 2025 Planned End Date changed from 14 May 2025 to 1 Apr 2025.